Article

Younger, Minority SLE Patients at Higher Risk for Readmission

The first large-scale study of repeat hospitalizations in SLE finds one in six patients readmitted within 30 days of a hospitalization.

Yazdany J, Marafino BJ, Dean ML, et al, Thirty-day Hospital Readmissions in Systemic Lupus Erythematosus: Predictors and Hospital and State-level Variation.Arthritis & Rheumatology (2014)  doi: 10.1002/art.38768. Accepted article published online before print.

Black and Hispanic patients with systemic lupus erythematosus (SLE) are more likely than Caucasians to be readmitted within 30 days of a hospitalization, according to a large study of hospital discharge databases.

Women younger than 65 also had a significantly increased risk of readmission, possibly due to more severe disease.

The study of all-cause readmissions included about 56,000 hospitalizations among SLE patients in roughly 85% of US hospitals in five states (California, Florida, New York, Utah, and Washington) between 2008 and 2009. It found that about one in six hospitalized SLE patients were readmitted within 30 days – some repeatedly. Not surprisingly, more severe disease significantly increased the risk of readmission.

Among 4,916 individual patients, those with Medicare or Medicaid were significantly more likely to be readmitted than the 30%  who had private insurance.

Among SLE-related clinical conditions, more than one-third of the 9,244 readmissions were due to lupus nephritis and chronic renal failure. Serositis and thrombocytopenia also triggered readmission.

A different study published earlier this year found that serious infections are leading causes of hospitalization and death in SLE, particularly among patients with lupus nephritis.

 

 

 

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.